« Return to News | Drug Sponsors

Valeant Pharma acquires 19.9% minority equity investment in Brazilian biotech

Tuesday, March 13, 2012 06:00 AM

Valeant Pharmaceuticals International has acquired a 19.9% minority equity investment in Pele Nova Biotecnologia, a Brazilian research company focused on tissue regeneration. 

In return for the ownership, for which Valeant paid less than $10 million, Valeant will have representation on Pele Nova's board of directors, a reduced royalty rate for Regederm, rights to all future products in Brazil and the first right of refusal for global product rights. 

Regederm, a biologic wound healing product, was recently approved in Brazil and is expected to launch in April.

"We are excited about another unique opportunity in Brazil," said J. Michael Pearson, chairman and CEO of Valeant. "Our investment in Pele Nova follows the successful approval for Regederm, originally licensed by Instituto Terapeutico Delta, a company that was acquired by Valeant in 2010, and is expected to provide us with a potential pipeline of biologic compounds in the future." 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.